Oncolytics provides update on pancreatic cancer program for pelareorep

Oncolytics provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma, or PDAC. Oncolytics’ collaborator, The Pancreatic Cancer Action Network, or PanCAN, a pancreatic cancer patient advocacy organization, advised the company that it is implementing a strategic re-evaluation of the Precision Promise program and will not be adding any new investigational therapies to the platform until the re-evaluation is complete. Oncolytics and PanCAN had previously planned to initiate a Phase 3 trial using the Precision PromiseSM platform in H1 2024. Oncolytics now plans to conduct an adaptive Phase 3 program of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab, similar to the Precision Promise study and manage it directly within our Clinical Group and a contract research organization, or CRO, with the goal of enrolling the first patient in mid-2024. Additionally, Oncolytics and PanCAN confirmed that PanCAN will continue with its plans to grant US$5 million to Oncolytics as part of the Therapeutic Accelerator Award for the new Phase 2 GOBLET study arm evaluating the combination of pelareorep and modified Folfirinox in pancreatic cancer patients.